Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Acta Diabetologica
Published in: Acta Diabetologica 5/2015

01-10-2015 | Original Article

Membranous nephropathy and cerebellar degeneration with anti-GAD antibodies in type 2 diabetes mellitus

Authors: Franco Folli, Giuseppe Daniele, Sherry Werner, Subash Kamath, Jose Velez Munera, Hanna Abboud, Paolo Fanti

Published in: Acta Diabetologica | Issue 5/2015

Login to get access

Abstract

Aims

To study the potential pathogenic significance of the coexistence of membranous nephropathy, cerebellar degeneration and anti-glutamic acid decarboxylase (GAD) autoantibodies in patients with diabetes.

Methods

We performed a direct immunocytochemistry on human kidney slides, electron microscopy on human kidney biopsy, direct immunofluorescence on human kidney biopsy. Baboon and rat kidney cell lines were fractionated and subjected to western blotting with antibodies to GAD.

Results

In this patient we demonstrate the presence of autoantibodies to GAD, which is highly enriched in podocytes plasma membrane and tubular cells of the kidney as well as sub-endothelial IgG and complement C3 deposits in the glomerular basement membrane (GBM).

Conclusions

We hypothesize the existence in this patient of a common autoimmune pathogenic mechanism with GAD as the autoantigenic determinant, underlying cerebellar degeneration and membranous nephropathy.
Literature
1.
Solimena M, Folli F, Denis-Donini S et al (1988) Autoantibodies to glutamic acid decarboxylase in a patient with stiff-man syndrome, epilepsy, and type I diabetes mellitus. N Engl J Med 318:1012–1020CrossRefPubMed
2.
Solimena M, Folli F, Aparisi R et al (1990) Autoantibodies to GABA-ergic neurons and pancreatic beta cells in stiff-man syndrome. N Engl J Med 322:1555–1560CrossRefPubMed
3.
Baekkeskov S, Aanstoot HJ, Christgau S et al (1990) Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature 347:151–156CrossRefPubMed
4.
5.
Bonifacio E, Krumsiek J, Winkler C et al (2014) A strategy to find gene combinations that identify children who progress rapidly to type 1 diabetes after islet autoantibody seroconversion. Acta Diabetol 51:403–411CrossRefPubMed
6.
7.
Mahadeb YP, Gruson D, Buysschaert M et al (2014) What are the characteristics of phenotypic type 2 diabetic with low-titer GAD65 antibodies? Acta Diabetol 51:103–111CrossRefPubMed
8.
Fiorina P, Venturini M, Folli F et al (2005) Natural history of kidney graft survival, hypertrophy, and vascular function in end-stage renal disease type 1 diabetic kidney-transplanted patients: beneficial impact of pancreas and successful islet cotransplantation. Diabetes Care 28:1303–1310CrossRefPubMed
9.
10.
Couser WG, Nangaku M (2006) Cellular and molecular biology of membranous nephropathy. J Nephrol 19:699–705PubMed
11.
Kasinath BS, Mujais SK, Spargo BH et al (1983) Non diabetic renal disease in patients with diabetes mellitus. Am J Med 75:613–617CrossRefPubMed
12.
Mundel P, Shankland SJ (2002) Podocyte biology and response to injury. J Am Soc Nephrol 13:3005–3015CrossRefPubMed
13.
Rego Filho EA, Mello SF, Omuro AM et al (2003) Simultaneous onset of steroid-sensitive nephrotic syndrome and type 1 diabetes. J Pediatr (Rio J) 79:557–560CrossRef
14.
Dittrich K, Knerr I, Rascher W et al (2006) Transient insulin-dependent diabetes mellitus in children with steroid-dependent idiopathic nephrotic syndrome during tacrolimus treatment. Pediatr Nephrol 21:958–961CrossRefPubMed
15.
Folli G, Pollak VE, Reid RT et al (1958) Electron-microscopic studies of reversible glomerular lesions in the adult nephrotic syndrome. Ann Intern Med 49:775–795CrossRefPubMed
16.
Honnorat J, Saiz A, Giometto B et al (2001) Cerebellar ataxia with anti-glutamic acid decarboxylase antibodies: study of 14 patients. Arch Neurol 58:225–230CrossRefPubMed
17.
Reetz A, Solimena M, Matteoli M et al (1991) GABA and pancreatic beta-cells: colocalization of glutamic acid decarboxylase (GAD) and GABA with synaptic-like microvesicles suggests their role in GABA storage and secretion. EMBO J 10:1275–1284PubMedCentralPubMed
18.
Monroy A, Kamath S, Chavez AO et al (2009) Impaired regulation of the TNF-alpha converting enzyme/tissue inhibitor of metalloproteinase 3 proteolytic system in skeletal muscle of obese type 2 diabetic patients: a new mechanism of insulin resistance in humans. Diabetologia 52:2169–2181PubMedCentralCrossRefPubMed
19.
Moersch FP, Woltman HW (1956) Progressive fluctuating muscular rigidity and spasm (“stiff-man” syndrome); report of a case and some observations in 13 other cases. Mayo Clin Proc 31:421–427
20.
Peltola J, Kulmala P, Isojarvi J et al (2000) Autoantibodies to glutamic acid decarboxylase in patients with therapy-resistant epilepsy. Neurology 55:46–50CrossRefPubMed
21.
McKnight K, Jiang Y, Hart Y et al (2005) Serum antibodies in epilepsy and seizure associated disorders. Neurology 65:1730–1736CrossRefPubMed
22.
Giometto B, Nicolao P, Macucci M et al (1998) Temporal-lobe epilepsy associated with glutamic-acid-decarboxylase autoantibodies. Lancet 352:457CrossRefPubMed
23.
Kwan P, Sills GJ, Kelly K et al (2000) Glutamic acid decarboxylase autoantibodies in controlled and uncontrolled epilepsy: a pilot study. Epilepsy Res 42:191–195CrossRefPubMed
24.
Barker R, Revesz T, Thom M et al (1998) Review of 23 patients affected by the stiff man syndrome: clinical subdivision into stiff trunk (man) syndrome, stiff limb syndrome, and progressive encephalomyelitis with rigidity. J Neurol Neurosurg Psychiatry 65:633–640PubMedCentralCrossRefPubMed
25.
Dinkel K, Meinck HM, Jury KM et al (1998) Inhibition of gamma-aminobutyric acid synthesis by glutamic acid decarboxylase autoantibodies in stiff-man syndrome. Ann Neurol 44:194–201CrossRefPubMed
26.
27.
Daw K, Ujihara N, Aktinson M et al (1996) Glutamic acid decarboxylase autoantibodies in Stiff-man syndrome and insulin-dependent diabetes mellitus exhibit similarities and differences in epitope recognition. J Immunol 156:818–825PubMed
28.
Folli G, Onida L (1959) Biopsy and electron microscopy of the kidney. Sci Med Ital 8:19–58PubMed
29.
vanDamme BJC, Fleuren GJ, Bakker WW et al (1978) Experimental glomerulonephritis in the rat induced by antibodies directed against tubular antigens: part IV: fixed glomerular antigens in the pathogenesis of heterologous immune complex glomerulonephritis. Lab Invest 38:502–510
30.
Kerjaschski D, Farquhar MG (1983) Immunochemical localization of the Heymann nephritis antigen (gp330) in glomerular epithelial cells of normal Lewis rats. J Exp Med 157:667–686CrossRef
31.
Neale TJ, Wilson CB (1982) Glomerular antigens in Heymann’s nephritis: reactivity of eluted and circulating antibody. J Immunol 128:323–330PubMed
32.
Madaio MP, Salant DJ, Cohen AJ et al (1983) Comparative study of in situ immune deposit formation in active and passive Heymann nephritis. Kidney Int 23:498–505CrossRefPubMed
33.
Couser WG, Salant DJ (1980) In situ immune complex formation and glomerular injury. Kidney Int 17:1–13CrossRefPubMed
34.
Beck LH Jr, Bonegio RG, Lambeau G et al (2009) M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 361:11–21PubMedCentralCrossRefPubMed
35.
36.
Hoxha E, Harendza S, Zahner G et al (2011) An immunofluorescence test for phospholipase-A2-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis. Nephrol Dial Transplant 26:2526–2532CrossRefPubMed
37.
Debiec H, Ronco P (2011) PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy. N Engl J Med 364:689–690CrossRefPubMed
38.
Prunotto M, Carnevali ML, Candiano G et al (2010) Autoimmunity in membranous nephropathy targets aldose reductase and SOD2. J Am Soc Nephrol 21:507–519PubMedCentralCrossRefPubMed
39.
Bruschi M, Carnevali ML, Murtas C et al (2011) Direct characterization of target podocyte antigens and auto-antibodies in human membranous glomerulonephritis: alfa-enolase and borderline antigens. J Proteomics 74:2008–2017CrossRefPubMed
Metadata
Title
Membranous nephropathy and cerebellar degeneration with anti-GAD antibodies in type 2 diabetes mellitus
Authors
Franco Folli
Giuseppe Daniele
Sherry Werner
Subash Kamath
Jose Velez Munera
Hanna Abboud
Paolo Fanti
Publication date
01-10-2015
Publisher
Springer Milan
Published in
Acta Diabetologica / Issue 5/2015
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-015-0728-x

Other articles of this Issue 5/2015

Acta Diabetologica 5/2015 Go to the issue

Original Article

Glycaemic load versus carbohydrate counting for insulin bolus calculation in patients with type 1 diabetes on insulin pump

Original Article

Lipid accumulation product and visceral adiposity index are effective markers for identifying the metabolically obese normal-weight phenotype

Original Article

Clinical factors that predict remission of diabetes after different bariatric surgical procedures: interdisciplinary group of bariatric surgery of Verona (G.I.C.O.V.)

Original Article

Co-transplantation of autologous MSCs delays islet allograft rejection and generates a local immunoprivileged site

Original Article

High-sensitivity C-reactive protein, but not white blood cell count, independently predicted incident diabetes in a Japanese health screening population

Original Article

Advanced glycation end product (AGE)-induced hepatic stellate cell activation via autophagy contributes to hepatitis C-related fibrosis
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits